Drugs / PMS-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06946511 | Aug 2025 → Jan 2026 overdue | dementia | Ruijin Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PMS-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06946511 ↗ |
| Modality | Peptide | “Peptide PMS-001 Intravenous Injection” NCT06946511 ↗ |
| Route | Intravenous | “Participants will receive intravenous injections of PMS-001.” NCT06946511 ↗ |